Holmusk Expands NeuroBlu Dataset to 46 Million Patients with Neurology and Biomarker Data

Holmusk announced in a press release the expansion of its NeuroBlu platform to include data from over 46 million de-identified patient records, an increase of more than 5 million. The update, known as NeuroBlu 26R2, adds two top ranked neurological health systems and introduces structured biomarker data and validated outcomes measures across neurological disease areas.

The expanded dataset covers conditions such as Alzheimer's disease, Parkinson's disease, dementia, epilepsy, and migraine. It includes over 4,600 tau biomarker assay results and 32,000 total biomarker-linked records for Alzheimer's research. NeuroBlu 26R2 also incorporates validated outcomes measures such as the Mini-Mental State Examination, Epworth Sleepiness Scale, and Numeric Rating Scale for pain.

According to the release, 41 percent of patients in NeuroBlu carry both neurological and behavioral health diagnoses within the same longitudinal record. This design enables research into comorbid conditions such as Alzheimer's disease with psychiatric outcomes data or Parkinson's disease with linked sleep disorder information.

NeuroBlu 26R2 is available to life sciences, biopharma, and biotech organizations. The dataset is linkage ready through the DataVant ecosystem, allowing integration with claims datasets for broader longitudinal analysis.